We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Symphogen Launches New Website and Marketing Materials

News  
Published: December 21, 2005
 
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above. ✖

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy
Read time: Less than a minute

Symphogen has recently launched a new website accompanied by several new factsheets detailing the company, technology and products.

Symphogen’s recombinant polyclonal antibody products are geared to the treatment of diseases caused by complex target antigens such as cancer, infectious diseases, transplantation rejection, and allergy.

The Company’s lead product, which combines 25 different recombinant anti-Rhesus D (RhD) antibodies for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) and the prevention of Hemolytic Disease of Newborns (HDN), is expected to enter the clinic in 2006.

Related Topic Pages
Infectious Diseases
The Immune System
Advertisement
Advertisement
Advertisement
Decoratvive background images
Never miss a story
with the Breaking Science News daily newsletter